WHITMER & WORRALL, LLC
Lobbying for CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Coalition to promote lowering prescription drug prices.
Issues related to prescription drug prices. S.1041 Affordable Prescriptions for Patients Act. Fair Accountability and Innovative Research Drug Pricing Act. S.229 Drug Price Transparency for Consumers Act.
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2023. S. 1097 Interagency Patent Coordination Act. Medication Affordability and Patent Integrity Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act H.R. 3160 & S. 1533, the PREVAIL Act S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025 S.43 Skinny Labels, Big Savings Act S. 1954, the Biosimilar Red Tape Elimination Act S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act S.1040 Drug Competition Enhancement Act
Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act.